Triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15 …

Outcomes have improved significantly for many women diagnosed with breast cancer. For
the heterogeneous group of tumours lacking expression of the oestrogen, progesterone and …

Epidermal growth factor receptor (EGFR) is frequently overexpressed in triple-negative
breast cancer and is emerging as a therapeutic target. EGFR gene copy number alteration …

Objectives Traditional cancer therapy and regular immunotherapy are ineffective for treating
triple‐negative breast cancer (TNBC) patients. Recently, chimeric antigen receptor …

Triple-negative breast cancer (TNBC) is an aggressive cancer subtype for which effective
therapies are lacking. Epidermal growth factor receptor (EGFR) is overexpressed in various …

Triple negative breast cancer (TNBC) is a heterogeneous disease with aggressive behavior
and poor prognosis. Genomic sequencing has detected a distinctive mutational portrait of …

The majority of samples in existing tumour biobanks are surgical specimens of primary
tumours. Insights into tumour biology, such as intratumoural heterogeneity, tumour–host …

Triple-negative breast cancer (TNBC) is a subset of breast cancer with aggressive
characteristics and few therapeutic options. The lack of an appropriate therapeutic target is a …

Background: Lung cancer is the leading cause of brain metastases (BM). The identification
of driver oncogenes and matched targeted therapies has improved outcome in non-small …

Importance Parkinson disease (PD) has been reported to be associated with a general
reduced risk of cancer. These studies were mainly carried out in Western populations and …